vTv Therapeutics annual return on equity
2025
vTv Therapeutics Return on Equity (ROE) Growth & History (VTVT)
vTv Therapeutics's return on equity was −70.40% for fiscal 2025.
View full vTv Therapeutics company overviewvTv Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −70.40% | — |
vTv Therapeutics quarterly return on equity
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −15.49% | +97.71 pp |
| Q1 2026 | 2026-03-31 | 31.26% | +81.88 pp |
| Q4 2025 | 2025-12-31 | −10.58% | +16.14 pp |
| Q3 2025 | 2025-09-30 | −23.73% | +6.65 pp |
| Q2 2025 | 2025-06-30 | −113.20% | −85.40 pp |
| Q1 2025 | 2025-03-31 | −50.62% | — |
| Q4 2024 | 2024-12-31 | −26.71% | — |
| Q3 2024 | 2024-09-30 | −30.38% | — |
| Q2 2024 | 2024-06-30 | −27.80% | — |
vTv Therapeutics return on equity trends
The latest reported quarter, Q2 2026, shows −15.49%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review vTv Therapeutics source filings ↗